

30 July 2024

ASX ANNOUNCEMENT

MVP SUCCESSFULLY COMPLETES INSTITUTIONAL PLACEMENT AND INSTITUTIONAL COMPONENT OF ENTITLEMENT OFFER

Medical Developments International Limited (ASX:MVP) (**MVP** or the **Company**) is pleased to announce the successful completion of the institutional placement (**Placement**) and the institutional component (**Institutional Entitlement Offer**) of its 1 for 7.35 pro rata accelerated non-renounceable entitlement offer (**Entitlement Offer** and, together with the Placement, the **Offer**) of new fully paid ordinary shares in MVP (**New Shares**). The details of this Offer were announced to the ASX on **26 July 2024**.

The Placement and Institutional Entitlement Offer (together, the **Institutional Offer**) closed at 5.00pm on **29 July 2024**. The Institutional Offer had strong support from institutional investors, with a take-up rate from eligible institutional shareholders of approximately 82%.

The Institutional Offer raised gross proceeds of approximately A\$6.9 million at an offer price of A\$0.38 per New Share, consisting of approximately A\$5.55 million under the Placement and approximately A\$1.34 million under the Institutional Entitlement Offer. The Placement attracted strong demand from existing institutional shareholders of the Company and introduced several new institutional investors to the MVP register.

Gordon Naylor, Company Chair, said:

"We're pleased to have such strong support from our institutional shareholders who have continued to invest in MVP through this financing. I would also like to welcome our new institutional investors to our share register. This raise has provided funding that will support delivery of our growth strategy. We will keep you updated as we progress."

No shareholder approval is required in connection with the issue of New Shares under the Institutional Offer.¹

New Shares subscribed for under the Institutional Offer are expected to be settled on **Monday, 5 August 2024** and to be issued on **Tuesday, 6 August 2024**. New Shares issued under the Institutional Offer will rank equally with existing fully paid ordinary shares in MVP as at their date of issue.

As announced to ASX on **Friday, 26 July 2024**, the Offer is fully underwritten and lead managed by Bell Potter Securities Limited (**Bell Potter**). It is expected to raise approximately A\$10.0 million, comprising the Institutional Offer of approximately A\$6.9 million and Retail Entitlement Offer of approximately A\$3.1 million.

MVP expects the ASX to lift its trading halt and for MVP's ordinary shares to recommence trading on the ASX on an ex-entitlements basis from market open today.

Retail Entitlement Offer

The retail component of the fully underwritten Entitlement Offer (**Retail Entitlement Offer**) is expected to open at 9.00am on **Friday, 2 August 2024** and close at 5.00pm (Sydney, Australia time) on **Thursday, 22 August 2024**. The despatch of (and providing electronic access to) the retail entitlement offer booklet for the Retail Entitlement

¹ The Company has received an ASX waiver in relation to ASX Listing Rule 7.1 to enable it to calculate its available placement capacity for the Placement using an expanded issued capital base assuming the fully underwritten Entitlement Offer was completed.

Offer (**Booklet**), with personalised entitlement and acceptance forms for eligible retail shareholders, is scheduled to occur on **2 August 2024**.

Eligible retail shareholders will be able to subscribe for 1 New Share for every 7.35 existing ordinary shares held in MVP as at 7.00pm (Sydney, Australia time) on the record date of **Tuesday, 30 July 2024**, at the same offer price of A\$0.38 per New Share, being the same as the price paid per New Share by investors in the Institutional Offer.

Under the Retail Entitlement Offer, eligible retail shareholders who subscribe for their full entitlement to New Shares may also apply for additional New Shares (**Additional New Shares**) in excess of their entitlement up to a maximum of 100% of their entitlement under a 'top up' facility. Allocations for Additional New Shares will be determined by MVP in its absolute discretion and any allotment of Additional New Shares is not guaranteed.

The terms and conditions under which eligible retail shareholders may apply for New Shares and Additional New Shares under the Retail Entitlement Offer are outlined in the Booklet. Copies of the Booklet will be available on the ASX website and our website at from **2 August 2024**.

Offer Timetable²

Event	Date / Time
Trading halt	Friday, 26 July 2024
Announcement of results of the completion of Placement and Institutional Entitlement Offer and recommencement of trading	Tuesday, 30 July 2024
Record date for Entitlement Offer	7.00pm, Tuesday, 30 July 2024
Retail Offer Booklet dispatched and made available electronically Retail Entitlement Offer opening date	Friday, 2 August 2024
Settlement of New Shares under the Placement and Institutional Entitlement Offer	Monday, 5 August 2024
Issue and normal trading of New Shares under the Placement and Institutional Entitlement Offer	Tuesday, 6 August 2024
Retail Entitlement Offer closing date	5.00pm, Thursday, 22 August 2024
Announcement of results of Retail Entitlement Offer	Tuesday, 27 August 2024
Issue of New Shares under the Retail Entitlement Offer	Wednesday, 28 August 2024
Trading of New Shares under the Retail Entitlement Offer expected to commence	Thursday, 29 August 2024
Holding statement sent to Retail holders	Friday, 30 August 2024

² All dates and times are indicative and MVP reserves the right to amend any or all of these events, dates and times subject to the *Corporations Act 2001* (Cth), the ASX Listing Rules and other applicable laws. All times and dates are in reference to Sydney, Australia time.

FURTHER INFORMATION

Medical Developments International Limited is being advised by Bell Potter Securities Limited as Lead Managers and underwriter to the Offer.

NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES

~END~

Authorised for release by the Board of Directors.

For further information please contact

Brent MacGregor
CEO Medical Developments International
+ 61 3 9547 1888

Anita James
CFO Medical Developments International
+ 61 3 9547 1888

About Medical Developments International Ltd

MVP is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MVP is a leader in emergency pain relief and respiratory products. The Company manufactures Pentrox®, a fast-acting non-opioid trauma & emergency pain relief product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defence Forces, Sports Medicine and for analgesia during short surgical procedures as well as in other medical applications.